LIVIVO - Search results -

Search results

Result 1 - 10 of total 14

Search options

Article ; Online: An Unrecognized Problem in Optimizing Antimicrobial Therapy: Significant Residual Volume Remaining in Intravenous Tubing With Extended-Infusion Piperacillin-Tazobactam.

Peyko, Vincent

2021 Volume 36, Issue 2, Page(s) 194–197

Abstract: The fundamental process of medication therapy is that a medication is ordered, verified, and entirely administered to the patient. An unrecognized phenomenon across the antimicrobial landscape may be residual volume remaining within intravenous tubing, ... ...

Abstract	The fundamental process of medication therapy is that a medication is ordered, verified, and entirely administered to the patient. An unrecognized phenomenon across the antimicrobial landscape may be residual volume remaining within intravenous tubing, never getting to the patient. Evidence suggests that 40-60% of an antimicrobial may remain in the intravenous tubing. Across the globe, residual volume may be affecting thousands to millions of patients receiving antimicrobials each year. While residual volume may be profound for all antimicrobials, the challenges to remedy this problem are more imposing with extended-infusion administration techniques. The purpose of this article is to highlight residual volume as a potential problem in optimizing extended-infusion antimicrobial therapy with agents like piperacillin-tazobactam. Furthermore, to emphasize that recognizing this issue for antimicrobials and other medications is imperative for providers to assure every patient is receiving the medication ordered, in its entirety, to avert medication errors and optimize patient care.
MeSH term(s)	Humans ; Anti-Bacterial Agents ; Piperacillin ; Residual Volume ; Penicillanic Acid ; Piperacillin, Tazobactam Drug Combination ; Anti-Infective Agents/therapeutic use ; Infusions, Intravenous
Chemical Substances	Anti-Bacterial Agents ; Piperacillin (X00B0D5O0E) ; Penicillanic Acid (87-53-6) ; Piperacillin, Tazobactam Drug Combination (157044-21-8) ; Anti-Infective Agents
Language	English
Publishing date	2021-07-16
Publishing country	United States
Document type	Letter
ZDB-ID	1027474-1
ISSN	1531-1937 ; 0897-1900
ISSN (online)	1531-1937
ISSN	0897-1900
DOI	10.1177/08971900211033462
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2893: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Use of Intravenous Hydroxocobalamin without Methylene Blue for Refractory Vasoplegic Syndrome After Cardiopulmonary Bypass.

Peyko, Vincent / Finamore, Michael

The American journal of case reports

2021 Volume 22, Page(s) e930890

Abstract: BACKGROUND Cardiac vasoplegic syndrome is a form of vasodilatory shock characterized by profound vasodilation and low systemic vascular resistance, which results in significant hypotension despite high cardiac output and appropriate fluid resuscitation. ... ...

Abstract	BACKGROUND Cardiac vasoplegic syndrome is a form of vasodilatory shock characterized by profound vasodilation and low systemic vascular resistance, which results in significant hypotension despite high cardiac output and appropriate fluid resuscitation. In up to 45% of patients, cardiopulmonary bypass (CPB) can precipitate vasoplegic syndrome. Vasoplegic syndrome after CPB that is refractory to other vasopressors, such as catecholamine and vasopressin, has been successfully treated with inhibitors of the nitric oxide (NO) system, such as methylene blue and hydroxocobalamin. Methylene blue has been the treatment of choice because of its effectiveness for both prevention and rescue therapy. Hydroxocobalamin has demonstrated efficacy in combination with methylene blue, and also on its own when vasoplegic syndrome is refractory to methylene blue. CASE REPORT We present 2 cases that expand upon the existing evidence supporting the efficacy of hydroxocobalamin as a first-line option for inhibiting the NO system in vasoplegic syndrome that is refractory to other vasopressors. Specifically, we demonstrate the appropriate and successful use of hydroxocobalamin alone to treat refractory vasoplegic syndrome after CPB. CONCLUSIONS Refractory vasoplegic syndrome that occurs after CPB has been successfully treated with inhibitors of the NO system, such as methylene blue and hydroxocobalamin. The present cases expand upon the scant existing evidence of the efficacy of hydroxocobalamin as an appropriate option for refractory vasoplegic syndrome.
MeSH term(s)	Cardiopulmonary Bypass/adverse effects ; Humans ; Hydroxocobalamin/therapeutic use ; Hypotension ; Methylene Blue/therapeutic use ; Vasoplegia/drug therapy ; Vasoplegia/etiology
Chemical Substances	Hydroxocobalamin (Q40X8H422O) ; Methylene Blue (T42P99266K)
Language	English
Publishing date	2021-06-18
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	2517183-5
ISSN	1941-5923 ; 1941-5923
ISSN (online)	1941-5923
ISSN	1941-5923
DOI	10.12659/AJCR.930890
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Epinephrine Auto-Injection After Allergic Reaction Leading to Gas Gangrene of the Leg.

Peyko, Vincent / Shams, Darius / Lauver, Allison R

The American journal of case reports

2021 Volume 22, Page(s) e930889

Abstract: BACKGROUND Clostridial myonecrosis, also known as gas gangrene, is a highly lethal necrotizing soft tissue infection. While commonly associated with trauma, clostridial myonecrosis may be the result of parenteral injection of medications. Epinephrine is ... ...

Abstract	BACKGROUND Clostridial myonecrosis, also known as gas gangrene, is a highly lethal necrotizing soft tissue infection. While commonly associated with trauma, clostridial myonecrosis may be the result of parenteral injection of medications. Epinephrine is the most commonly reported medication leading to gas gangrene. CASE REPORT A 60-year-old man presented to the Emergency Department (ED) with "the worst pain in his life" to the right thigh near the site at which he auto-injected epinephrine after multiple bee stings 10-11 h prior to arrival. Initial heart rate was 112 beats/min but all other vital signs were unremarkable at presentation. Due to extreme pain, a computed tomography (CT) scan was ordered, revealing prominent gas within the anterior compartment of the right thigh, mostly involving the vastus lateralis and rectus femoris, suggesting necrotizing fasciitis. Antimicrobials were initiated immediately and the patient was taken for surgical debridement within 70 min after obtaining the CT results. Clostridium perfringens was cultured from the patient's tissue. After several surgical debridement's, appropriate antimicrobial therapy, supportive care, and wound care, the patient's limb remained intact and he was discharged after 11 days. CONCLUSIONS With millions of epinephrine auto-injectors prescribed yearly in the United States, awareness of clostridial gas gangrene following epinephrine auto-injection for the provider may help guide decision-making in patients presenting with extreme pain, redness, or swelling near the injection site after epinephrine injection.
MeSH term(s)	Animals ; Anti-Bacterial Agents/therapeutic use ; Bees ; Clostridium perfringens/isolation & purification ; Debridement ; Epinephrine/administration & dosage ; Epinephrine/adverse effects ; Gas Gangrene/etiology ; Gas Gangrene/therapy ; Humans ; Hypersensitivity ; Injections, Subcutaneous ; Insect Bites and Stings/therapy ; Leg/diagnostic imaging ; Male ; Tomography, X-Ray Computed
Chemical Substances	Anti-Bacterial Agents ; Epinephrine (YKH834O4BH)
Language	English
Publishing date	2021-04-21
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	2517183-5
ISSN	1941-5923 ; 1941-5923
ISSN (online)	1941-5923
ISSN	1941-5923
DOI	10.12659/AJCR.930889
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A Comparison of Adjusted Versus Unadjusted Doses of Polymyxin B Based on Renal Function and Incidence of Acute Kidney Injury.

Peyko, Vincent / Cohen, Henry

Journal of pharmacy practice

2018 Volume 33, Issue 3, Page(s) 255–261

Abstract: Purpose: To determine whether or not polymyxin B needs dose adjustments based on renal function by comparing the incidence of acute kidney injury (AKI) in patients whose polymyxin B doses were adjusted versus not adjusted according to renal function.: ...

Abstract	Purpose: To determine whether or not polymyxin B needs dose adjustments based on renal function by comparing the incidence of acute kidney injury (AKI) in patients whose polymyxin B doses were adjusted versus not adjusted according to renal function. Methods: This was a single-center, prospective study with a retrospective cohort taking place in an acute care community hospital. Forty-two patients treated with polymyxin B were evaluated between April 2012 and December 2015. The primary outcome was incidence of AKI at day 7 after initiation of polymyxin B therapy with secondary outcomes including microbiological cure, clinical cure, and 30-day mortality. Results: There was no difference in the incidence of AKI at day 7 in patients with polymyxin B doses adjusted according to renal function versus patients without polymyxin B dose adjustment (20.0% vs 18.2%; Conclusion: The results from this study support the use of polymyxin B without any dose adjustment in the setting of renal impairment.
MeSH term(s)	Acute Kidney Injury/chemically induced ; Acute Kidney Injury/diagnosis ; Acute Kidney Injury/epidemiology ; Anti-Bacterial Agents/adverse effects ; Humans ; Incidence ; Polymyxin B/adverse effects ; Prospective Studies ; Retrospective Studies
Chemical Substances	Anti-Bacterial Agents ; Polymyxin B (J2VZ07J96K)
Language	English
Publishing date	2018-09-06
Publishing country	United States
Document type	Journal Article
ZDB-ID	1027474-1
ISSN	1531-1937 ; 0897-1900
ISSN (online)	1531-1937
ISSN	0897-1900
DOI	10.1177/0897190018798881
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2893: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Novel approach to vancomycin level monitoring: Impact of a multidisciplinary monitoring system on timing of vancomycin levels.

Peyko, Vincent / Friedman-Jakubovics, Michelle

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

2018 Volume 75, Issue 3, Page(s) 121–126

Abstract: Purpose: A novel approach to vancomycin level monitoring is described.: Methods: Vancomycin trough orders were added to the medication ordering system of a large teaching hospital and were generated when vancomycin was ordered. Pharmacists adjusted ... ...

Abstract	Purpose: A novel approach to vancomycin level monitoring is described. Methods: Vancomycin trough orders were added to the medication ordering system of a large teaching hospital and were generated when vancomycin was ordered. Pharmacists adjusted the order time so that the level was drawn appropriately. After pharmacist validation, the trough order appeared within the nursing medication list, and nurses were required to document when the level was drawn. Outcomes were evaluated before (retrospective group) and after (prospective group) implementation of this initiative. Results: Among all patients for whom a vancomycin level was drawn, 24.0% of patients in the retrospective group had their first vancomycin level drawn within 2 hours of true trough, compared with 87.2% of patients in the prospective group ( Conclusion: A novel multidisciplinary approach to vancomycin trough monitoring involving automatic generation of trough orders, pharmacist validation of trough orders, and inclusion of trough orders in the nursing medication administration record was successful in significantly improving timing of vancomycin trough levels.
MeSH term(s)	Anti-Bacterial Agents/blood ; Drug Monitoring/methods ; Drug Monitoring/trends ; Female ; Humans ; Male ; Nurse's Role ; Patient Care Team/trends ; Pharmacists/trends ; Professional Role ; Prospective Studies ; Retrospective Studies ; Time Factors ; Vancomycin/blood
Chemical Substances	Anti-Bacterial Agents ; Vancomycin (6Q205EH1VU)
Language	English
Publishing date	2018-02-22
Publishing country	England
Document type	Journal Article
ZDB-ID	1224627-x
ISSN	1535-2900 ; 1079-2082
ISSN (online)	1535-2900
ISSN	1079-2082
DOI	10.2146/ajhp160760
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 419: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis.

Peyko, Vincent / Ladd, Helena / Cutrona, Anthony

Case reports in infectious diseases

2020 Volume 2020, Page(s) 8811798

Abstract: Remdesivir is a nucleoside analog prodrug with broad-spectrum antiviral activity, including against coronaviruses. This has prioritized the inclusion of remdesivir in coronavirus disease 2019 (COVID-19) clinical trials. The United States Food and Drug ... ...

Abstract	Remdesivir is a nucleoside analog prodrug with broad-spectrum antiviral activity, including against coronaviruses. This has prioritized the inclusion of remdesivir in coronavirus disease 2019 (COVID-19) clinical trials. The United States Food and Drug Administration has granted emergency use authorization for remdesivir. This emergency use authorization does not recommend the use of remdesivir in patients with estimated glomerular filtration rate (eGFR) less than 30 mL/min unless the benefits outweigh the risks. To date, there are no studies and scant information in the literature evaluating remdesivir utilization in patients with eGFR less than 30 mL/min or receiving hemodialysis. With little utilization data for patients with acute or chronic kidney injury, remdesivir may not be considered, leaving this patient population without the opportunity of a potentially beneficial treatment option. We present a case of one patient with eGFR less than 30 mL/min that required hemodialysis in which remdesivir was safely initiated, with therapy completed without any serious adverse events.
Language	English
Publishing date	2020-12-27
Publishing country	Egypt
Document type	Case Reports
ZDB-ID	2627642-2
ISSN	2090-6633 ; 2090-6625
ISSN (online)	2090-6633
ISSN	2090-6625
DOI	10.1155/2020/8811798
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A Case Report of a 74-Year-Old Immunocompromised Host Diagnosed with Pulmonary Blastomycosis and Pulmonary Hemorrhage.

Abbas, Aubrey / Yankle, Jaclyn M / Apostolis, Michael / Limbu, Indra / Peyko, Vincent

The American journal of case reports

2022 Volume 23, Page(s) e935059

Abstract: BACKGROUND Blastomycosis is a rare opportunistic disease caused by inhalation of the fungus Blastomyces dermatitidis. Blastomycosis can occur in all individuals but is most commonly seen in immunocompromised hosts. If left untreated or not caught early ... ...

Abstract	BACKGROUND Blastomycosis is a rare opportunistic disease caused by inhalation of the fungus Blastomyces dermatitidis. Blastomycosis can occur in all individuals but is most commonly seen in immunocompromised hosts. If left untreated or not caught early enough, blastomycosis can progress to fulminant multilobar pneumonia, acute respiratory distress syndrome (ARDS), and even death. CASE REPORT A 74-year-old immunocompromised man in northeast Ohio presented to the Emergency Department with shortness of breath and hemoptysis. The patient had a negative evaluation for a gastrointestinal bleed and was found to have significant blood collection in the larynx and trachea. A bronchoscopy demonstrated right upper lobe hemorrhage and an infection with Blastomyces species. The patient was started on amphotericin B 5 mg/kg every 24 h for severe blastomycosis. The patient continued to have pulmonary hemorrhage and progressed to multilobar pneumonia and ARDS. Ultimately, the patient died due to respiratory distress after being hospitalized for 5 days. CONCLUSIONS Blastomycosis can present with multiple clinical manifestations, including pulmonary hemorrhage, in severe disease. Diagnostic delay of blastomycosis is common owing to a nonspecific patient presentation. Blastomycosis is an opportunistic infection; therefore, the fungus can be more commonly seen within immunocompromised hosts. The combination of diagnostic delay and immunocompromised hosts leads to an increased mortality rate from blastomycosis infections.
MeSH term(s)	Aged ; Blastomyces ; Blastomycosis/diagnosis ; Delayed Diagnosis ; Hemoptysis ; Humans ; Immunocompromised Host ; Male
Language	English
Publishing date	2022-01-09
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	2517183-5
ISSN	1941-5923 ; 1941-5923
ISSN (online)	1941-5923
ISSN	1941-5923
DOI	10.12659/AJCR.935059
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: 4-Factor Prothrombin Complex Concentrate Administration via Intraosseous Access for Urgent Reversal of Warfarin.

Peyko, Vincent / Shams, Darius / Urbanski, Richard / Noga, Joseph

The Journal of emergency medicine

2019 Volume 57, Issue 1, Page(s) 82–84

Abstract: Background: Vitamin K antagonist (VKA) reversal in patients with acute major bleeding and coagulopathy is an example of an urgent intervention in the emergency department. Intravenous (IV) prothrombin complex concentrate (PCC) may reverse VKA-induced ... ...

Abstract	Background: Vitamin K antagonist (VKA) reversal in patients with acute major bleeding and coagulopathy is an example of an urgent intervention in the emergency department. Intravenous (IV) prothrombin complex concentrate (PCC) may reverse VKA-induced coagulopathy in <30 min. In patients lacking IV access, effective PCC administration becomes problematic. No previous case reports have documented PCC infusion via intraosseous (IO) or alternative routes in this setting. Case report: A 74-year-old man presented to the emergency department (ED) after a head injury, with sudden onset of left-sided facial droop, weakness, hypertension, and dizziness. Initial vital signs include blood pressure of 221/102 mm Hg, a heart rate of 75 beats/min, and oxygen saturation of 96% on room air. Warfarin 3 mg once daily was among his medications. His international normalized ratio (INR) was 3.9 with a computed tomography scan showing intraparenchymal hemorrhage in the right temporal lobe. Multiple attempts for IV access at various sites were unsuccessful. Therefore, IO access was established. Because of his prolonged prothrombin time, elevated INR, and intraparenchymal hemorrhage, the decision was made to use 4-factor PCC to reverse the supratherapeutic INR. The INR normalized as an emergent right parietal hematoma evacuation was performed. After an inpatient course, the patient was eventually discharged. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: VKAs, like warfarin, are commonly prescribed medications. When life-threatening hemorrhage is present, rapid reversal of a VKA-induced coagulopathy may be a life-saving therapy. In the event that IV access has not been established, we have demonstrated that IO access is a viable alternative route for PCC administration.
MeSH term(s)	Aged ; Anticoagulants/adverse effects ; Blood Coagulation Factors/administration & dosage ; Blood Coagulation Factors/therapeutic use ; Dizziness/etiology ; Hemorrhage/drug therapy ; Hemorrhage/prevention & control ; Humans ; Hypertension/etiology ; Infusions, Intraosseous/methods ; Male ; Muscle Weakness/etiology ; Time Factors ; Warfarin/adverse effects ; Warfarin/antagonists & inhibitors
Chemical Substances	Anticoagulants ; Blood Coagulation Factors ; prothrombin complex concentrates (37224-63-8) ; Warfarin (5Q7ZVV76EI)
Language	English
Publishing date	2019-05-03
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	605559-x
ISSN	0736-4679
ISSN	0736-4679
DOI	10.1016/j.jemermed.2019.03.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1895: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pericardial effusion and cardiac tamponade requiring pericardial window in an otherwise healthy 30-year-old patient with COVID-19: a case report.

Walker, Christina / Peyko, Vincent / Farrell, Charles / Awad-Spirtos, Jeanine / Adamo, Matthew / Scrocco, John

Journal of medical case reports

2020 Volume 14, Issue 1, Page(s) 158

Abstract: Background: This case report demonstrates pericardial effusion, acute pericarditis, and cardiac tamponade in an otherwise healthy woman who had a positive test result for coronavirus disease 2019. Few case reports have been documented on patients with ... ...

Abstract	Background: This case report demonstrates pericardial effusion, acute pericarditis, and cardiac tamponade in an otherwise healthy woman who had a positive test result for coronavirus disease 2019. Few case reports have been documented on patients with this presentation, and it is important to share novel presentations of the disease as they are discovered. Case presentation: A Caucasian patient with coronavirus disease 2019 returned to the emergency department of our hospital 2 days after her initial visit with worsening chest pain and shortness of breath. Imaging revealed new pericardial effusion since the previous visit. The patient became hypotensive, was taken for pericardial window for cardiac tamponade with a drain placed, and was treated for acute pericarditis. Conclusion: Much is still unknown about the implications of coronavirus disease 2019. With the novel coronavirus disease 2019 pandemic, research is still in process, and we are slowly learning about new signs and symptoms of the disease. This case report documents a lesser-known presentation of a patient with coronavirus disease 2019 and will help to further understanding of a rare presentation.
MeSH term(s)	Adult ; Betacoronavirus ; COVID-19 ; Cardiac Tamponade/virology ; Chest Pain ; Coronavirus Infections/complications ; Female ; Humans ; Pandemics ; Pericardial Effusion/virology ; Pericardial Window Techniques ; Pericarditis/virology ; Pneumonia, Viral/complications ; SARS-CoV-2
Keywords	covid19
Language	English
Publishing date	2020-09-09
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	2269805-X
ISSN	1752-1947 ; 1752-1947
ISSN (online)	1752-1947
ISSN	1752-1947
DOI	10.1186/s13256-020-02467-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Prospective Comparison of Acute Kidney Injury During Treatment With the Combination of Piperacillin-Tazobactam and Vancomycin Versus the Combination of Cefepime or Meropenem and Vancomycin.

Peyko, Vincent / Smalley, Samantha / Cohen, Henry

Journal of pharmacy practice

2017 Volume 30, Issue 2, Page(s) 209–213

Abstract: Purpose: To prospectively evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving the combination of piperacillin-tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin for greater than ... ...

Abstract	Purpose: To prospectively evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving the combination of piperacillin-tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin for greater than 72 hours. Methods: This was a prospective, open-label cohort study at a community academic medical center involving adult patients over a 3-month time period who received either the combination of piperacillin-tazobactam and vancomycin or the combination of cefepime or meropenem and vancomycin for greater than 72 hours. The patients were evaluated for AKI, defined using specific criteria introduced by Kidney Disease: Improving global outcomes (KDIGO) acute kidney injury work group in 2012. Results: A total of 85 patients receiving either antimicrobial combination were evaluated for AKI. The incidence of AKI was significantly higher in the piperacillin-tazobactam and vancomycin group (37.3%) compared with the cefepime or meropenem and vancomycin group (7.7%; χ Conclusion: The result of this study suggests that the risk of developing AKI is increased in patients receiving the combination of piperacillin-tazobactam and vancomycin versus those receiving the combination of cefepime or meropenem and vancomycin.
MeSH term(s)	Acute Kidney Injury/diagnosis ; Acute Kidney Injury/drug therapy ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/adverse effects ; Cephalosporins/administration & dosage ; Cephalosporins/adverse effects ; Cohort Studies ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; Penicillanic Acid/administration & dosage ; Penicillanic Acid/adverse effects ; Penicillanic Acid/analogs & derivatives ; Piperacillin/administration & dosage ; Piperacillin/adverse effects ; Prospective Studies ; Thienamycins/administration & dosage ; Thienamycins/adverse effects ; Treatment Outcome ; Vancomycin/administration & dosage ; Vancomycin/adverse effects
Chemical Substances	Anti-Bacterial Agents ; Cephalosporins ; Thienamycins ; piperacillin, tazobactam drug combination (157044-21-8) ; Vancomycin (6Q205EH1VU) ; cefepime (807PW4VQE3) ; Penicillanic Acid (87-53-6) ; meropenem (FV9J3JU8B1) ; Piperacillin (X00B0D5O0E)
Language	English
Publishing date	2017-04
Publishing country	United States
Document type	Comparative Study ; Journal Article
ZDB-ID	1027474-1
ISSN	1531-1937 ; 0897-1900
ISSN (online)	1531-1937
ISSN	0897-1900
DOI	10.1177/0897190016628960
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2893: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito